Hologic Inc.
Hologic Reports Q3 2025 Earnings Exceeding Guidance
Summary
Hologic, Inc. reported its financial results for the third quarter of fiscal 2025, showing revenue of $1,023.8 million, which exceeded the guidance range of $1,000 to $1,010 million. GAAP diluted EPS of $0.86 increased by 4.9% year-over-year, and non-GAAP diluted EPS of $1.08 exceeded the guidance range of $1.04 to $1.07. The company's financial performance was driven by robust molecular diagnostics sales, international growth, and strategic acquisitions. Hologic also provided updated financial guidance for the fourth quarter and full fiscal year 2025, anticipating continued revenue growth and faster non-GAAP EPS growth.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement